THE PRESENTATION AND MANAGEMENT OF PITUITARY TUMOURS
Keywords:
Prolactinomas; Dopaminergic agonists; Cabergoline; Hyperprolactinemia.Abstract
Prolactin-secreting tumors of the pituitary gland, also known as prolactinomas, are the most common secretory tumors of the pituitary gland, accounting for up to 40 percent of pituitary adenomas. Prolactinomas can lead to a wide variety of symptoms, either due to mass effect or hypersecretion of prolactin. This articl illustrates the evaluation, treatment.diagnosis.
References
SL Samson, AH Hamrahian, S Ezzat, Committee ANaPS, (ACE) ACoE
American Association of Clinical Endocrinologists, American College Of Endocrinology Disease State Clinical Review: Clinical relevance of macroprolactin in the absence or presence of true hyperprolactinemia Endocr Pract, 21 (2015), pp. 1427-1435 H Duskin-Bitan, I Shimon
Prolactinomas in males: any differences? Pituitary, 23 (2020), pp. 52-57
L Vilar, J Abucham, JL Albuquerque, et al. Controversial issues in the management of hyperprolactinemia and prolactinomas - an overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism
Arch Endocrinol Metab, 62 (2018), pp. 236-263 L Kasuki, L Vieira Neto, MR. Gadelha
Cabergoline treatment in acromegaly: cons Endocrine, 46 (2014), pp. 220-225
AH Zamanipoor Najafabadi, IM Zandbergen, F de Vries, et al. Surgery as a viable alternative first-line treatment for prolactinoma patients. a systematic review and meta-analysis J Clin Endocrinol Metab (2020), p. 105
T Mancini, FF Casanueva, A. Giustina Hyperprolactinemia and prolactinomas Endocrinol Metabol Clinics N Am, 37 (2008), pp. 67-99
J Buvat, A Lemaire, M Buvat-Herbaut, G. Marcolin [Prolactin determination in impotence], 18, Presse medicale, Paris, France (1983), p. 1167 1989
JA. Schlechte Clinical practice. Prolactinoma N Engl J Med, 349 (2003), pp. 2035-2041
ME. Molitch Disorders of prolactin secretion Endocrinol Metabol Clin N Am, 30 (2001), pp. 585-610
L Vilar, MC Freitas, LA Naves, et al. Diagnosis and management of hyperprolactinemia: results of a Brazilian multicenter study with 1234 patients
J Endocrinolog Invest, 31 (2008), pp. 436-444
F Devuyst, P Kazakou, D Balériaux, et al. Central diabetes insipidus and pituitary stalk thickening in adults: distinction of neoplastic from non-neoplastic lesions Eur J Endocrinol, 181 (2020), pp. 95-105
A Glezer, MD. Bronstein [Prolactinoma]
Arq Bras Endocrinol Metabol, 58 (2014), pp. 118-123 S.
Petersenn W Raber, A Gessl, P Nowotny, H. Vierhapper Hyperprolactinaemia in hypothyroidism: clinical significance and impact of TSH normalization Clin Endocrinol (Oxf), 58 (2003), pp. 185-191
